Double-stranded RNA impairs epithelial barrier formation by redirecting airway basal cell differentiation

The airways that carry air into our lungs are lined with a delicate, living wall. This wall, known as the epithelium, acts as a gatekeeper, keeping out dust, pollen, and viruses while letting oxygen pass through. To function correctly, this wall must be built from scratch whenever it is damaged, a process driven by a specific group of stem cells called basal cells. These cells sit at the base of the tissue and divide to create new layers of specialized cells, such as ciliated cells that sweep away debris and goblet cells that produce mucus. For this new wall to be strong, the cells must lock together tightly using molecular seals called tight junctions. If these seals are weak or missing, the barrier becomes leaky, allowing irritants to slip inside and trigger inflammation, a condition often seen in chronic lung diseases like asthma.

Scientists have long known that viral infections can damage this protective wall, but the exact moment when the damage occurs has remained a mystery. Does the virus simply tear down an already finished wall, or does it sabotage the construction crew before the wall is even built? A new study from researchers at Nihon University in Japan investigates this critical question by focusing on the very early stages of airway repair. They discovered that when the body's immune system detects a specific signal from a virus, it prioritizes immediate defense over the essential work of building a strong barrier. This decision, while logical for fighting an infection, leaves the airway permanently vulnerable, potentially explaining why some people develop chronic breathing problems after a single viral illness.

To explore this, the researchers worked with human airway cells in a laboratory setting that mimics the inside of a lung. They used two types of cells: normal human bronchial epithelial cells and a specialized line of basal cells called VA10. The team grew these cells in a liquid environment for three days, a stage where the cells are undifferentiated and ready to begin their transformation. During this critical window, they introduced a substance called poly I:C. This molecule is a synthetic mimic of double-stranded RNA, a structure that viruses create when they replicate inside a cell. The human body recognizes this structure as a danger signal through a sensor on the cell surface known as Toll-like receptor 3, or TLR3 for short. By using poly I:C, the scientists could trigger the body's antiviral alarm without using a live virus, allowing them to observe the specific effects of that alarm on the construction process.

The results were striking. When the cells were exposed to the viral mimic during those first three days, the barrier they eventually formed was significantly weaker than the barriers formed by cells that were not exposed. The researchers measured this weakness in two ways. First, they checked the electrical resistance across the layer of cells; a healthy, tight barrier resists the flow of electricity, but the treated cells showed a sharp drop in resistance. Second, they tested how easily a fluorescent dye could pass through the layer. In the treated cells, the dye leaked through much more easily, confirming that the seals between the cells were broken. This damage occurred even though the cells were grown in a clean environment after the initial exposure, proving that the viral signal had permanently altered the cells' ability to build a proper wall.

The study then looked deeper to understand how this happened. The researchers found that the damage was not caused by the virus itself, but by the cell's own reaction to it. When they silenced the TLR3 sensor or a key protein it uses to send signals, called TRIF, the cells were able to build a strong barrier even in the presence of the viral mimic. This confirmed that the immune response pathway was the direct cause of the barrier failure. The team also tested other common immune triggers, such as signals from bacteria, and found that those did not cause the same damage. In fact, one bacterial signal actually helped the barrier form, highlighting that the disruption was specific to the viral defense mechanism.

To see what was happening inside the cells, the researchers analyzed their genetic activity at two different times: three days after exposure, when the cells were just starting to change, and ten days later, when the barrier was fully formed. The early analysis revealed a dramatic shift in the cells' priorities. The cells immediately turned on a massive set of genes designed to fight viruses, a state known as the antiviral response. At the same time, they turned off the genes responsible for building the structural components of the airway wall. Specifically, the cells stopped producing key proteins like filaggrin and desmoglein-1, which act as the mortar and bricks for the tight junctions. Without these materials, the cells could not assemble the tight seals needed to keep the barrier intact.

The researchers also investigated whether the antiviral chemicals themselves, known as interferons, were the direct cause of the damage. They treated the cells with interferon-alpha and interferon-beta, the very signals the cells produce during an infection. Surprisingly, this treatment alone did not weaken the barrier. This suggests that the problem is not just the presence of these chemicals, but the complex internal reprogramming that happens when the cell decides to fight a virus. The cell essentially pauses its construction work to focus entirely on defense, and in doing so, it fails to lay down the foundation for a healthy barrier.

By the tenth day, the situation had evolved into a second phase. The cells that had been exposed to the viral mimic were now in a state of chronic inflammation. They were producing high levels of inflammatory signals and genes associated with tissue scarring and remodeling. This suggests that the initial failure to build a strong wall led to a long-term cycle of damage and poor repair. The airway tissue remained in a state of vulnerability, unable to mature into a healthy, functional barrier. This two-phase response—first an immediate halt to construction in favor of defense, followed by a lingering state of inflammation and abnormal repair—provides a clear mechanism for how a short-term viral infection can lead to long-term lung disease.

The study concludes that the vulnerability of the airway in conditions like asthma may not just be a matter of weak genes or environmental irritants, but a consequence of how the body's immune system handles the early stages of repair. When basal cells sense a viral threat, they make a trade-off: they sacrifice the immediate integrity of the barrier to mount a defense. While this protects the body from the virus in the short term, it compromises the long-term health of the lung lining. The findings suggest that the path to chronic airway disease can begin the moment a stem cell decides to fight a virus, leaving a lasting imprint on the tissue that makes it susceptible to future problems. This insight shifts the focus from simply treating the infection to understanding how the immune response itself can inadvertently damage the very structures it is trying to protect.